Grant Sweep

Consolidated research funding across disease areas and research fields — federal, foundation, state & industry sources in one filterable place.

← Back to opportunities
OpenR35NHLBIClinical trial: Optional / allowed

NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)

National Heart, Lung, and Blood Institute (NHLBI) · NIH Institute/Center · RFA-HL-26-003

Source: Grants.gov · View original posting ↗

Award
Amount not listed
Deadline
Apr 28, 2027
Letter of intent
Mechanism
R35
Duration
Expected awards
Funding cycle
One-time
Open date
Apr 26, 2024
Total funding
Clinical trial
Optional / allowed
Established investigatorSmall businessGovernmentHigher educationNonprofitForeign entities

Description

The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PDs/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).

Data notes: award amount not published in the source feed.